Close Menu
November 05, 2020

Clinical Insights from Multi-omic Studies on Esophageal Cancer

Genome Webinar

Professor of Cancer Prevention,
Hutchison-MRC Research Centre, University of Cambridge

In this webinar, Rebecca Fitzgerald of the Hutchison-MRC Research Center at the University of Cambridge, will give a broad overview of the epidemiology and clinical features of esophageal cancer. Focussing on esophageal adenocarcinoma she will discuss the progress that has been made in understanding the molecular landscape of this cancer from whole genome sequencing and RNA sequencing data. She will describe how although the driver gene landscape is highly heterogeneous the mutational signatures and cell signalling pathways converge to indicate the likely cause and vulnerabilities in esophageal adenocarcinoma which pave the way for new therapy approaches.

In the final part of the webinar Rebecca will discuss how earlier detection of relapse and indicators of response to therapy would help to tailor treatment. Blood biopsy to detect circulating tumor DNA is one such approach and Dr. Fitzgerald will present data to show the potential of a ctDNA mutation panel to detect relapse post-surgery in patients with esophageal adenocarcinoma in a retrospective study.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.